Review Article *Open Access*

WM PUBLICATIONS

Journal of Nursing Research Perspectives

DOI: doi.org/10.63721/26JJNRP0108

Clinical Differentiation of Gilbert Syndrome, Crigler-Najjar Syndrome, and β-Thalassemia Trait

Jayesh Trivedi[1]*, Raja Joshi[4], Harsh Patel[4], Rashid Khan[2], Sanjay Gehlot[3], Atul Gupta[3], Keyur Soni[4], Ayushya Pal Singh[4], Sudeep Deswal[4], Apurva Chaudhary[4], Shubham Balki[4], Prem Panpaliya[4] and Saurabh Dubey[4]

[1]Professor Department of General Medicine Pacific Medical College & Hospital, Udaipur, India
[2]Associate Professor, Department of General Medicine Pacific Medical College & Hospital, Udaipur, India
[3]Senior Resident, Department of General Medicine Pacific Medical College & Hospital, Udaipur, India
[4]Post Graduate Residents, Department of General Medicine Pacific Medical College & Hospital, Udaipur, India

Citation: *Jayesh Trivedi, Raja Joshi, Harsh Patel, Rashid Khan, Sanjay Gehlot, et al. (2026) Clinical Differentiation of Gilbert Syndrome, Crigler-Najjar Syndrome, and β-Thalassemia Trait. J of Nur Res Pers 2(1), 1-11. WMJ/JNRP-108*

Abstract

Unconjugated hyperbilirubinemia in adolescents and young adults has to be differentiated clinically as it is associated with different clinical presentation, most commonly Gilbert syndrome (GS) – a benign hereditary bilirubin conjugation defect – versus increased bilirubin production from mild haemolytic disorders such as β-thalassemia trait, with the rare Crigler-Najjar syndromes as important considerations. This publication is made to educates clinicians and medical students. Basic laboratory tests and clinical clues will be important. Liver function tests (LFTs) and hemolysis markers (complete blood count, reticulocyte count, lactate dehydrogenase, etc.), followed by targeted tests such as haemoglobin electrophoresis for hemoglobinopathies and provocative tests (fasting or rifampicin test, phenobarbital trial) for conjugation defects We emphasize how inexpensive investigations can confirm the diagnosis, avoiding unnecessary costly workups. Key distinguishing features of GS, Crigler-Najjar type 2, and β-thalassemia trait – including typical bilirubin levels, hematologic indices, genetic basis, and management – are summarized in a comparative table. Early recognition of these benign conditions is crucial for patient reassurance, appropriate counselling (e.g. for carrier traits), and preventing unwarranted interventions.

***Corresponding author**: Jayesh Trivedi, Professor Department of General Medicine Pacific Medical College & Hospital, Udaipur, India.

Submitted: 17.02.2026 **Accepted**: 21.02.2026 **Published**: 28.03.2026

To distinguish Gilbert syndrome, Crigler-Najjar (type 2), and β-thalassemia trait, one should understand the clinical and laboratory profile of each:

Gilbert Syndrome (GS)

Gilbert syndrome is the most common cause of isolated unconjugatedhy perbilirubinemia in young adults. It is caused by a genetic polymorphism in the promoter of the UGT1A1 gene (most often an extra TA repeat in the TATA box region), resulting in ~30% reduced activity of bilirubin-UGT enzyme in the liver. The inheritance pattern of GS has traditionally been described as autosomal recessive, though it can appear in heterozygotes with contributing factors; overall it is a benign constitutional trait. Epidemiology: GS occurs in roughly 3–12% of various populations. It is often unrecognized; family history may not be obvious (only ~5–10% of relatives of GS patients are clinically diagnosed). GS tends to manifest after puberty, with a male predominance (male-to-female ~2–3:1), possibly due to inhibitory effects of estrogen on bilirubin metabolism or higher bilirubin production in males.

Clinical Features: Patients are usually asymptomatic except for jaundice. Mild scleral icterus may wax and wane, often triggered by fasting, stress, illness, dehydration, or exertion. No signs of liver disease are present (no hepatosplenomegaly, no choluria since unconjugated bilirubin is not excreted in urine). Some patients report non-specific fatigue or abdominal discomfort, but objective clinical issues are absent.

Laboratory Findings: Total bilirubin in GS is mildly elevated, typically ranging from normal up to 3–4 mg/dL. During intercurrent stress or fasting it may rise, but usually stays <6 mg/dL. Importantly, the direct bilirubin is normal (unconjugated fraction > 80–90%). Liver transaminases, alkaline phosphatase, and other liver function tests are normal. Haemoglobin and other labs are normal; there is no evidence of hemolysis (reticulocyte count and LDH are normal in pure GS). A mild elevation of isolated indirect bilirubin in an otherwise healthy adolescent/adult virtually points to GS as the "default" diagnosis. Indeed, Gilbert's syndrome should be suspected in any mild unconjugatedhy perbilirubinemia with normal liver function and no hemolysis.

Confirmation: Given its benign nature, GS often does not require confirmatory testing beyond history and labs. If confirmation is needed (e.g. patient anxiety or diagnostic ambiguity), one can perform the rifampicin test or fasting test, as described earlier, which will be positive in GS. Genetic testing for the UGT1A1 promoter mutation is the gold standard but is costly and not routinely done unless needed for research or unusual cases. In our case patient, after excluding hemolysis and finding normal LFT aside from bilirubin ~9.7 mg/dL (predominantly indirect ~9.3), we performed a rifampicin test: his bilirubin spiked further a few hours after rifampicin, supporting Gilbert syndrome superimposed on his thalassemia trait.

Management and prognosis: GS requires no treatment. Patients are counselled regarding the benign course – it does not cause liver damage or morbidity. They should be informed that jaundice may recur during stress, fasting, or illness, but this is harmless. Simple measures like maintaining hydration and regular meals can minimize episodes. In rare instances where appearance of jaundice is problematic (e.g. cosmetic concerns), low-dose phenobarbital can reduce bilirubin levels, but this is seldom recommended given GS's benign nature. Interestingly, GS has been associated with a reduced risk of cardiovascular disease due to bilirubin's antioxidant properties, so it may even have a protective effect. On the other hand, GS (especially when co-inherited in haemolytic disorders) can predispose to pigment gallstones due to chronically elevated bilirubin in bile. Overall, the prognosis is excellent; GS patients live a normal life and should simply be followed with routine care.

Crigler-Najjar Syndrome (Type II)

Crigler-Najjar syndrome type II (Arias syndrome) is a rare hereditary unconjugatedhy perbilirubinemia caused by a partial deficiency of UGT1A1 enzyme activity. It is autosomal recessive. While Crigler-Najjar type I results from virtually complete absence of UGT1A1 (and presents in neonates with severe jaundice and kernicterus), type II patients have ~10–30% of normal enzyme activity, enough to usually avoid kernicterus but still causing significant bilirubin elevation. Various point mutations in the coding region of UGT1A1 have been identified in CN2, as opposed to promoter variants in Gilbert. The incidence of all Crigler-Najjar types is extremely low (~1 per million births).

Clinical Features: CN type II often presents in infancy or childhood with persistent jaundice, but because the bilirubin is lower than in type I, patients often survive without exchange transfusions or transplant. They typically have unconjugated bilirubin levels in the range of 6–20 mg/dL lifelong. Jaundice may deepen with intercurrent illness. Unlike type I, neurological impairment is uncommon in type II, but mild cases of kernicterus have been reported under stress (since bilirubin can occasionally rise above 20 mg/dL). No other abnormalities are present – liver enzymes are normal, and there is no hemolysis. If the history is obtained, often neonatal jaundice was noted (sometimes treated as "physiologic jaundice" that never fully resolved). Some patients are not diagnosed until later if they present with prolonged jaundice and GS is suspected but the levels are higher than typical for GS.

Laboratory Findings: Total bilirubin is persistently elevated, usually between 7 and 18 mg/dL predominantly unconjugated. Direct bilirubin remains low (<~15% of total). Liver function tests aside from bilirubin are normal. There is no evidence of hemolysis (normal hemoglobin, retic, etc.). It can be challenging to distinguish CN2 from a severe form of GS based on labs alone, since there is some overlap (e.g. a GS patient fasting might reach 5–6 mg/dL, while a mild CN2 might run ~6–7 mg/dL). Thus, the phenobarbital test is often utilized: a CN2 patient will show a significant drop in bilirubin with phenobarbital but typically will not normalize, whereas a GS patient's modest bilirubin may normalize on phenobarbital. In one case report, a >30% reduction in bilirubin after one week of phenobarbital pointed to CN2, while GS cases in the series normalized completely. Genetic testing can confirm CN2 by identifying biallelic UGT1A1 mutations (different from the GS promoter variant), but such testing is rarely available outside specialized enters.

Management: The mainstay treatment for CN type II is phenobarbital, which induces the UGT1A1 enzyme and can reduce serum bilirubin by ~25–50%. Typical doses are 60–180 mg per day (in adults) or 5 mg/kg/day in children, titrated to effect. This often brings bilirubin down to safer levels (<10 mg/dL), greatly reducing any theoretical risk of kernicterus. Many CN2 patients take phenobarbital daily; others may use it intermittently during intercurrent illnesses when bilirubin rises. Aside from phenobarbital, some newer approaches (such as clofibrate or other enzyme inducers) have been tried with variable success. Unlike CN type I, phototherapy is usually not needed for CN2 except possibly in neonatal period, because levels are not extremely high. Liver transplant is not usually indicated in CN2, given the relatively benign course; patients generally have normal life expectancy with medication. They should avoid factors that can further raise bilirubin (certain drugs that inhibit UGT1A1, like some protease inhibitors or high-dose nicotinic acid, etc., and extreme fasting). Overall, with adherence to phenobarbital therapy, individuals with CN2 can remain healthy and rarely suffer neurological damage. Regular follow-up is advised to monitor bilirubin levels and drug side effects.

Beta-Thalassemia Trait (β-Thalassemia Minor)

β-Thalassemia trait is the heterozygous carrier state for β-thalassemia, an inherited defect in β-globin chain production of haemoglobin. It is highly prevalent in certain regions – for instance, an estimated 3–4% of the Indian population carries a β-thalassemia mutation (with higher rates in some communities) making it an important consideration in any microcytic anaemia or incidental lab finding. While β-thalassemia minor typically causes only a mild anaemia, it can contribute to unconjugated hyperbilirubinemia due to ongoing ineffective erythropoiesis and increased turnover of red cells.

Clinical Features: Most with β-thalassemia trait are asymptomatic or have mild fatigue. There is usually no overt jaundice in isolation; however, if jaundice is present in a carrier, it raises suspicion of a coexisting Gilbert syndrome (this co-inheritance is not uncommon and leads to higher bilirubin than either condition alone). Our case exemplifies this: a 17-year-old male with β-thalassemia trait had a disproportionately high bilirubin (~9 mg/dL) that could not be explained by the trait alone, leading to the diagnosis of concomitant GS. On examination, patients may have mild pallor. Scleral icterus may be subtle or absent unless bilirubin is >3 mg/dL (which usually requires an added factor like GS). The spleen is typically not enlarged in pure trait (unlike in thalassemia intermedia or major).

Laboratory Findings: Microcytic, hypochromic indices on CBC are the hallmark. Haemoglobin is near normal or slightly low (often ~10–13 g/dL). Mean

corpuscular volume (MCV) and mean corpuscular haemoglobin (MCH) are reduced (MCV often 60–75 FL). The RBC count is normal or elevated (a key clue differentiating from iron deficiency anaemia, where RBC count is low for the degree of anemia). Reticulocyte count may be normal or minimally elevated – the bone marrow compensates for some hemolysis, but in trait the hemolysis is not pronounced. Indirect bilirubin can be upper-normal or mildly high (e.g. ~1–3 mg/dL) due to turnover of microcytic, fragile RBCs. LDH and haptoglobin are usually normal in trait (unlike in hemolyticanemias). The definitive diagnostic test is haemoglobin electrophoresis or HPLC, which characteristically shows elevated HbA2 in β-thalassemia trait. Typically, HbA2 (normal ~2%) will be ≥4% (often 4–8%) in a carrier. A slight increase in fetalhemoglobin (HbF) (2–5%) may also be seen. In our patient, Hb electrophoresis revealed HbA2 of 5.0%, confirming the trait. Iron studies should be normal (or if iron deficiency coexists, HbA2 may be masked – iron repletion will unmask the high HbA2).

It is worth noting that by itself, β-thalassemia minor usually does not cause significant jaundice. In published series, many thalassemia minor patients have normal bilirubin unless they co-inherit GS or another haemolytic factor. The co-inheritance of GS in thalassemia or sickle cell patients is known to amplify jaundice levels. Therefore, diagnosing GS in a thalassemia carrier (or vice versa) is important so that the benign nature of the jaundice is recognized and the patient is not subjected to repeated evaluations.

Management: β-Thalassemia trait requires no active treatment for the mild anaemia. The key is counselling and family screening – patients should be informed they are carriers and advised about testing their partner, since two carriers have a 25% risk of an affected child (thalassemia major) which is a severe disease. They should also be cautioned against excessive iron supplementation unless iron deficiency is proven, because trait is often misdiagnosed as iron-deficiency anaemia; indiscriminate iron can lead to overload. Folic acid supplementation can be given if there is any evidence of increased hemolysis or to support erythropoiesis, though it's not strictly necessary in uncomplicated trait. The prognosis for β-thalassemia minor is excellent; it does not affect lifespan or cause organ damage. It does, however, confer a slight risk of gallstones over a lifetime due to increased bilirubin turnover, a risk exacerbated if Gilbert syndrome co-exists. Regular follow-up is not required unless there are changes in blood counts.

Comparative Summary

For clarity, Table 1 compares the distinguishing features of Gilbert syndrome, Crigler-Najjar syndrome (type II), and β-thalassemia trait:

Table 1: Key Differences between Gilbert Syndrome, Crigler-Najjar Type II, and β-Thalassemia Trait

Feature	Gilbert Syndrome (GS)	Crigler-Najjar Syndrome Type II	β-Thalassemia Trait
Genetic basis	UGT1A1 promoter variant (often homozygous TA7) causing ~30% enzyme activity. Inherited usually autosomal recessive (benign)	UGT1A1 coding region mutations causing <10–30% enzyme activity. Autosomal recessive	Heterozygous β-globin gene mutation (carrier state). Autosomal recessive disease (trait = one normal, one mutated gene)
Prevalence	Common: ~3–10% of general population (varies by ethnicity). M>F (2–3:1) after puberty.	Very rare: ~1 in 1,000,000. No sex predilection.	Common in high-prevalence areas. ~1.5% of global population are carriers; ~3–4% in India (higher in certain groups) .

Typical age of presentation	Late adolescence or young adult (jaundice often first noted in teens). Childhood onset is rare (GS manifests after puberty)	Often noted in infancy/early childhood (prolonged neonatal jaundice), but surviving patients present in childhood and remain jaundiced thereafter.	Usually identified in childhood via anemia screening. Trait is present from birth, but mild and often detected in teens/young adults during routine CBC. Jaundice is typically absent unless coexistent GS.
Serum bilirubin levels	Mildly elevated, usually <4 mg/dL (can fluctuate 1–6 mg/dL; rarely >6). Nearly all unconjugated (>80%).	Moderately elevated ~6–20 mg/dL unconjugated. Tends to be persistently high. Direct bilirubin normal. (Type I CN: >20–30 mg/dL extreme levels from neonatal period).	Normal or slight ↑ indirect bilirubin (often normal (<1.5) to ~3 mg/dL at most). Significant jaundice is not typical in trait alone. Conjugated fraction normal.
Liver function tests (ALT, AST, ALP)	Normal. (No hepatic inflammation or cholestasis)	Normal.	Normal (jaundice is pre-hepatic in origin).
Hematologic findings	Normal haemoglobin and CBC. No hemolysis (retic normal, LDH normal).	Normal CBC (no anaemia unless coincident issue). No hemolysis.	Microcytic hypochromic RBCs; mild anaemia or low-normal Hb. High RBC count relative to Hb. Peripheral smear: target cells. Elevated HbA2 (4–8%) on electrophoresis. Slight ↑retic may be present but not dramatic.
Clinical features	Intermittent jaundice (scleral icterus), often triggered by fasting, stress, dehydration. Otherwise, asymptomatic; no hepatosplenomegaly.	Persistent jaundice since infancy. Generally asymptomatic aside from yellow coloration. Rarely mild neurologic symptoms if bilirubin approaches >20 mg/dL (kernicterus is very rare in type II).	Usually no jaundice (unless co-inherited GS). Mild anemia symptoms possible (fatigue). No organ enlargement in trait (spleen normal).
Provocative test results	Fasting: bilirubin rises >50%. Rifampicin: bilirubin surge (positive test). Phenobarbital trial: bilirubin falls to normal.	Fasting: bilirubin may rise (less predictable). Rifampicin: not classically used. Phenobarbital trial: bilirubin drops ~30% but not to normal (diagnostic).	No specific bilirubin-provocation tests. (Mentzer index or RBC count can help distinguish from iron deficiency; Hb electrophoresis confirms).

Treatment	None required – reassurance and avoid precipitating factors. Phenobarbital can be used short-term if needed (not usually).	Phenobarbital is standard (induces UGT, ↓ bilirubin by ~25–50%). Usually 60–180 mg/d. Avoid agents that inhibit UGT1A1. Phototherapy in neonatal period if needed. Liver transplant rarely indicated (only if uncontrolled bilirubin).	No medical treatment needed for trait. Ensure genetic counselling (screen partner, prenatal testing if both parents carriers). Avoid misdiagnosis as iron deficiency – check iron status before giving iron. Folic acid supplements can be given.
Prognosis	Excellent. Lifelong benign fluctuant jaundice. No impact on survival or liver health. Slight risk of gallstones due to bilirubin.	Good. With phenobarbital, bilirubin can be kept in safer ranges. Normal lifespan if managed (kernicterus risk is minimal with treatment).	Excellent. Trait itself causes no serious health issues. Main concern is family planning (to avoid thalassemia major births). Mild anaemia persists but doesn't usually affect quality of life.

(References: Gilbert syndrome; Crigler-Najjar syndrome; β-thalassemia trait.)

References

1. Nath JD (2014) Familial association of Gilbert's and beta thalassemia trait. Chattagram-Maa-O-Shishu Hospital Med Coll J 1: 65-66.
2. Priyadarshini D, Amit Kumar Satapathy, Samarendra Mahapatro (2019) Gilbert syndrome in a young boy with thalassemia trait: a rare association. Int J ContempPediatr 6: 1373-1375.
3. Sinha R, S Dalal, K Sodhi (2015) Differentiating Gilbert Syndrome from Crigler-Najjar Syndrome Type 2 by Phenobarbitone Test. J Nepal Paediatric Soc 35: 82-84.
4. Stat Pearls (2025) Unconjugated Hyperbilirubinemia.
5. Stat Pearls (2024) Crigler-Najjar Syndrome.
6. Stat Pearls (2023) Beta Thalassemia.
7. Ellis E (2014) Gilbert syndrome in patients with inherited hemolyticanemia.
8. Arias IM (1962) Chronic unconjugated hyperbilirubinemia without overt hemolysis in adults. J Clin Invest 41: 2233-2245.
9. Bosma PJ, J R Chowdhury, C Bakker, S Gantla, A de Boer (1995) The genetic basis of reduced UGT1A1 expression in Gilbert's syndrome. N Engl J Med 333: 1171-1175.
10. VanWagner LB, Green RM (2015) Evaluating elevated bilirubin levels in asymptomatic adults. JAMA 313: 516-517.